Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts

Ver comunicado completo:


The justification for this consensus is the absence of local protocols on Medication-Related Osteonecrosis of the Jaws (MONJ), for prevention, evaluation, and treatment, involving physicians and dentists, leading to suspension of antiresorptive treatments, despite their benefit in the prevention of fragility fractures (40–70%). These fractures cause disability and mortality (80% and 20–30%, respectively), as opposed to the low risk associated with MONJ in osteoporotic (0.01–0.03%) and oncological patients (1.3–1.8%).